Speakers

Michael Berk

Professor Michael Berk

Chair of Psychiatry, Deakin University

Professor Michael Berk is currently a NHMRC L3 research Fellow and is Alfred Deakin Chair of Psychiatry at Deakin University and Barwon Health, where he heads the Institute for Innovation in Mental and Physical Health and Clinical Translation (IMPACT). He is also an Honorary Professorial Research fellow in the Department of Psychiatry, the Florey Institute for Neuroscience and Mental Health and Orygen Youth Health at Melbourne University, as well as in the School of Public Health and Preventive Medicine at Monash University. He has published over 1600 papers and is listed by Thompson Reuters ISI as highly cited (2015-2023). His major interests are in the discovery and implementation of novel therapies.
Adam Caplan

Adam Caplan

Founder and General Partner, Jumpspace Ventures

Jumspace Ventures is a New York based venture capital firm focused on breakthrough innovations in neuroscience and human-machine interfaces. The firm invests in early-stage companies advancing brain-computer interfaces, neuromodulation and neural diagnostics.

Adam is also a Co-Founder at Artisan Council, a digital marketing agency, as well as a Co-Founder and Board Member at Facteus, a provider of consumer transaction data to hedge funds.

Earlier in his career, Adam co-founded ID8 Investments, a diversified venture capital firm, as well as Super Rewards, a monetization solution for social network games which was acquired by Adknowledge in 2009. Before that, he worked as an investment banker with Morgan Stanley for eleven years, focusing on the emerging Internet and new media sectors.

Mark Cook

Professor Mark Cook

The Sir John Eccles Chair of Medicine and Director of Clinical Neurosciences at St. Vincent’s Hospital

Mark Cook is Professor of Biomedical Engineering and Sir John Eccles Chair of Medicine, University of Melbourne, and Director of Neurology at St. Vincent’s Hospital Melbourne. He is a neurologist recognised internationally for his expertise in epilepsy management, particularly imaging and surgical planning. In 2023 he was named an Officer in the General Division of the Order of Australia (AO) for distinguished service to neurological medicine and research through contributions to the treatment of epilepsy. He has worked closely with engineers for most of his career, developing novel therapies for epilepsy. His interests have included experimental models of epilepsy and seizure prediction, and he has led 3 first in human clinical studies of epilepsy devices, and is involved in the commercialisation of an implantable seizure detection device – Epiminder – that received FDA approval in May 2025.

Hon Weng Chong

Hon Weng Chong

CEO and Founder, Cortical Labs

Hon Weng Chong is the founder and CEO of Cortical Labs, a Deep Technology startup looking to fuse biological material with computing chips resulting in a proto-AGI device. Previously he was the founder and CTO of CliniCloud; a medtech startup that built full-stack connected medical devices that was backed by Tencent and Ping An ventures.

Hon Weng trained as a medical doctor at The University of Melbourne and was exposed to the world of technology entrepreneurialism during his research year at Johns Hopkins. In addition to being a medical doctor, Hon Weng is a full-stack software engineer and a machine learning enthusiast. Hon Weng is a Forbes 30 under 30 recipient in 2016.

Rachel de las Heras

Rachel de las Heras

CEO, Ceretas

Ceretas is building the next- generation portable therapeutic ultrasound platform to non-invasively treat neurodegenerative diseases.

Rachel was formerly the Ultrasound Product Development Manager at the Queensland Brain Institute (QBI), The University of Queensland. Under her leadership, she has overseen medical device development directed at establishing the safety of therapeutic ultrasound in Alzheimer’s disease through the successful completion of a first-in-human study.

Rachel has developed diagnostic medical devices whilst at Panbio (now Abbott formerly Alere) and Cellestis (now Qiagen). Most notably co-inventing and developing QuantiFERON Monitor, a diagnostic to improve the clinical management of transplant patients now marketed by Qiagen.

Rachel has commercialised research discoveries whilst at UniQuest and has also held several commercial and business development roles.

Since completing her PhD in molecular neuroscience, Rachel has worked in leadership positions across various scientific disciplines including biochemistry, organic chemistry and engineering.

Trish Lavery

Trish Lavery

Visiting Fellow, School of Cybernetics, Australian National University

Trish Lavery is an academic and policy expert working at the Australian National University and currently leading a foresight project on the social and geopolitical aspects of emerging climate cooling technologies. Her work places human behaviour at the centre of strategy, futures, and strategic foresight. Trish has worked as part of the Policy Projects and Taskforce Office at the Department of the Prime Minister and Cabinet and as Strategic Foresight Counsellor for the Office of the Secretary-General, OECD. Prior to her role at the OECD, Trish worked for 10 years in the Australian Government’s environment directorate as a behavioural insights practitioner.
Rachel Levin

Rachel Levin

Investment Director, National Reconstruction Fund Corporation

The National Reconstruction Fund is a $15 billion fund established by the Australian government to help grow the economy and create jobs. The fund operates as an independent financier, separate from the government, and will invest in priority areas of the economy, including medical science, resources, defence capability, transport, and renewable energy.

Rachel is a biotech and medtech investor with experience across research (MSc, PhD, industry), startups, and big pharma.

Geoffrey Mackellar

Geoffrey Mackellar

CTO, EMOTIV

Dr. Geoff Mackellar is based in Sydney, Australia, where he heads EMOTIV’s R&D hub located at the Macquarie University Incubator. His leadership has been instrumental in EMOTIV’s mission to democratize brain research and make neurotechnology accessible to a global community of researchers and developers.

Geoff obtained his PhD in Laser Physics from Macquarie University between 1979 and 1985. Prior to that, they obtained a BSc(Hons1) in Physics(Hons), Mathematics, and Computing from the University of New England (AU) between 1975 and 1978.

Helen Macpherson

Dr Helen Macpherson

Senior Research Fellow, Institute for Physical Activity and Nutrition (IPAN), Deakin University

Dr Helen Macpherson is leading a program of dementia prevention research at Deakin University. Her work encompasses the identification and modification of health and lifestyle determinants of dementia risk, assessment of neurocognitive ageing and early detection of dementia and cognitive decline.

Dr Macpherson has received $4 million funding to support this research. She has expertise in the design and conduct of randomised controlled trials. Dr Macpherson also has experience working with large population-based data sets. She is currently supervising several PhD students using various neuroimaging techniques to study age-related changes in cognition. Drawing on her background in cognitive neuroscience and psychology, Dr Macpherson’s work is contributing to the important knowledge that dementia risk can be reduced by targeting health behaviours.

Dr Macpherson contributed to the development of Dementia Australia’s BrainTrack app, a pioneering tool designed for self-monitoring cognition, which has already reached 150,000 downloads.

Andrew Maxwell

Andrew Maxwell

Chairman, Cyban

Andrew is MD of Chatsworth Associates, working with innovators, and entrepreneurs to plan equity raisings, corporate transactions, and international business development programs. Andrew is currently the Chairman of Cyban, which has received funding from several notable funds, including Breakthrough Victoria. Cyban has developed a next generation brain pulse monitor that advances the treatment of brain injuries by delivering reliable information continuously. From 2021 – Feb 2024, Andrew was Investment Committee Chair and Venture Partner for Significant Early Venture Capital. As CEO of ESCOR Private Equity (a Smorgon Family Company), Andrew established and managed a $40m investment fund making investments in the IT, Internet, Biotech, Healthcare, Alternative Energy and Manufacturing technology sectors.
Nicholas Opie

Professor Nicholas Opie

CEO, Ultra Bionics and Founding Director, Synchron

Professor Nicholas Opie is a global expert in neural interfaces, and endovascular bionics pioneer.

He designed and developed the world’s first endovascular brain computer interface that can be implanted without invasive brain surgery. His creation, the Stentrode, is aimed at restoring communication, mobility and independence to people with paralysis. He is currently working to develop new neurotechnology to treat other neurological conditions including Epilepsy, depression and Parkinson’s.

Professor Opie earned his undergraduate degrees in Electrical and Computer Systems Engineering (Hons) and Science at Monash University, his PhD in retinal neuroprostheses at the University of Melbourne and his MBA from Melbourne Business School. He is a Professor, NHMRC Investigator Fellow and Head of the Vascular Bionics Laboratory within the Department of Medicine at the University of Melbourne where he has been awarded more than $30M in research funding to translate his technology from concept to clinic. He is also a Founding Director of Synchron Australia and Synchron Inc, raising more than $200M to commercialise the Stentrode System.

Professor Opie has published more than 70 peer-reviewed publications, including in Nature Biomedical Engineering and Nature Biotechnology, has presented his work at over 200 local and international conferences and is an inventor of over 110 patents. He has received numerous awards for his inventions, including Times Top 100 inventions in 2022.

Harikesh Pushpapathan

Harikesh Pushpapathan

General Partner, Stoic VC

Partner @ Stoic VC; an early stage venture fund solving our world’s most intractable problems by a) Redesigning human health b) supercharging compute c) rebalancing the earth. To do this, we partner with Uniseed – commercialisation body managing 65% of Australia R&D output. I currently sit on a few committees including Uniseed, Antler and NSW government’s Biosciences fund. Prior to this, I spent a few years investing personally, at other funds, fundraising for startups and building my own telehealth business. When I’m not investing or recovering from sporting injuries, I love to write – both in music and blogs.

Kathryn Sunn

Dr Kathryn Sunn

CEO, Celosia Therapeutics and Director of Commercialisation, Macquarie University

Celosia Therapeutics is a pre-clinical stage gene therapy company, developing solutions for neurodegenerative diseases that have limited alternative therapeutic options.

Dr. Sunn is renowned for her dynamic leadership and strategic vision in fostering technology collaborations and expanding commercial opportunities within the Australian research and early enterprise sectors. With extensive experience in intellectual property management, strategy, and business development, Dr. Sunn has held roles in two of Australia’s leading patent firms and has spearheaded the technology transfer units at the Australia’s largest universities. Her expertise lies in forging impactful strategic partnerships and delivering commercially focused advice to transform innovations into valuable assets.

Dr. Sunn holds a PhD in Medical Science with a specialisation in genetics from the Garvan Institute of Medical Research. She is a trained patent and trademark attorney in Australia and New Zealand. serving She is on the Board of Knowledge Commercialisation Australasia as well as on the boards of several Macquarie University startup companies.

Cassandra Szoeke

Professor Cassandra Szoeke

Lead, Women’s Healthy Ageing Program, Monash Centre for Health Research

Professor Cassandra Szoeke is a Consultant Neurologist, Author and Internationally awarded Academic. In addition to her medical qualifications and fellowship in the Royal College of Physicians she has a BSc with Honours in Genetics and PhD in Epidemiology, her postdoctoral studies at Stanford University CA, focused on public health and policy and her sabbatical at Oxford University focused on sex-specific medicine.

Cassandra is is the Inaugural Chair of the Asia-Pacific Node of the Women’s Brain Project. She has contributed to the development of national health policies, has sat on the Council of the Australian Medical Association, was appointed to Medical Panels by the Department of Health (Victoria) and has held Chief Health Advisor roles for the Australian Healthy Ageing Organisation and the National Council of Women.

TeamSlatts who is convening BrainTech 2025 acknowledges the Traditional Owners of the Countries on which we gather for our events. We recognise the sovereignty, knowledge and community of First Peoples and pay our respects to the Ancestors and Elders who pave the way for future Leaders.

We walk with great reverence on the various places TeamSlatts live, work and visit. Always was, always will be.